Oct. 24 - Lilly’s bargain gene therapy bet, Sanofi’s sliding vaccine sales and Blenrep’s return
Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales; FDA clears return of GSK’s once-withdrawn multiple myeloma drug; Chugai buys a kidney biotech; ICER targets rising launch prices; Biotech’s M&A outlook is uncertain. Track the deals that are happening here.
Unlock an accelerated route to the European market by leveraging MHRA’s recognition of FDA and other trusted global regulatory approvals.
Reveal the way ahead.
Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the company’s previous closing share price.
Chugai is acquiring partial rights to a marketed IgA nephropathy drug. Elsewhere, ICER claimed Americans are often “overpaying” for medicines and Summit raised $500 million.
